Is Chemours (CC) A Bargain As Its PFAS Settlement Clarifies Long Term Risks?

Chemours (CC) stock is in focus after the company agreed to a regulatory settlement over PFAS discharges, committing to a US$22.5 million civil penalty and US$90 million of long term mitigation projects.

See our latest analysis for Chemours.

The PFAS settlement landed after a strong run for Chemours, with the share price up 64.41% year to date at US$20.14. However, recent 30 day and 7 day share price returns of 9.77% and 4.87% respectively indicate that momentum has cooled and reflect longer term total shareholder returns that remain down over three and five years.

If this regulatory reset has you reviewing other opportunities in materials and infrastructure, it could be a good time to scan 35 power grid technology and infrastructure stocks

Chemours now carries clearer PFAS liabilities, a share price that has already climbed strongly this year, and an intrinsic value estimate implying a large discount. Is the stock still underappreciated, or are markets already pricing in future growth?

Most Popular Narrative: 24% Undervalued

Chemours is trading at $20.14 versus a widely followed fair value estimate of about $26.33, which frames the recent PFAS settlement against a still sizable valuation gap.

Progress in resolving legacy PFAS litigation risk, highlighted by the New Jersey settlement and insurance recoveries, has significantly improved long-term earnings visibility and reduced potential future cash outflows, removing a major overhang and enhancing free cash flow conversion.

Read the complete narrative.

Want to understand why this widely followed Chemours narrative still sees room above today’s price? The entire case leans on rising revenues, sharply higher margins and a very low future earnings multiple that contrasts with many peers.

Result: Fair Value of $26.33 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Chemours narrative still faces real pressure points, including unresolved PFAS litigation and tighter environmental rules that could increase costs and reduce profitability.

Find out about the key risks to this Chemours narrative.

Next Steps

If the mixed sentiment around Chemours has you on the fence, review the numbers and narrative now, then weigh both the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Chemours?

Do not stop with Chemours. Use this moment to refresh your watchlist with new ideas that match the way you like to invest.

• Hunt for potential bargains by scanning 41 high quality undervalued stocks and see which companies currently trade at a discount to their fundamentals.
• Prioritize resilience by reviewing 73 resilient stocks with low risk scores so you can focus on companies with steadier risk profiles.
• Target quality balance sheets with solid balance sheet and fundamentals stocks screener (47 results) and filter for businesses that pair financial strength with underlying fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com